Condition: Thrombocytopenia · Neonatal · Platelet Transfusion · Sponsor: NICHD Neonatal Research Network
The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
This description comes directly from the study's public registry record.
Ravi M Patel, MD · 404-727-5905 · rmpatel@emory.edu
Abhik Das, PhD · 301-230-4640 · adas@rti.org
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| Sharp Mary Birch Hospital for Women & Newborns | San Diego, California, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Northwestern Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| University of New Mexico | Albuquerque, New Mexico, United States | Recruiting |
| University of Rochester | Rochester, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Medical Center | Cincinnati, Ohio, United States | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06676904